Bispecific CD19-directed CD3-directed T Cell Engager class drugs

FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

1 result

Blincyto (blinatumomab)

(blinatumomab)

Manufacturer:Amgen Inc

Usage: BLINCYTO is indicated for treating CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients aged one month and older. It is used for those with minimal residual disease (MRD), relapsed or refractory disease, and during the consolidation phase of multiphase chemotherapy.